ADI vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 07, 2026

ADI

35.7
AI Score
VS
MRNA Wins

MRNA

37.1
AI Score

Investment Advisor Scores

ADI

36score
Recommendation
SELL

MRNA

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ADI MRNA Winner
Revenue 10.81B 534.00M ADI
Net Income 3.35B -2.13B ADI
Net Margin 31.0% -397.9% ADI
Operating Income 3.99B -2.20B ADI
ROE 10.0% -31.4% ADI
ROA 6.9% -19.4% ADI
Total Assets 48.42B 10.96B ADI
Cash 2.17B 1.72B ADI
Debt/Equity 0.20 0.09 MRNA
Current Ratio 1.25 2.29 MRNA
Free Cash Flow 3.45B -1.25B ADI

Relative Price Performance (Last 90 Days)

ADI 1M: +12.9% · 3M: +4.2% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

ADI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 64

RSI (14): 63.7 · Price: $410.08

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric ADI MRNA
Market Cap — —
Forward P/E 25.1 -41.0
Trailing P/E 49.9 —
Revenue (TTM) — —
Revenue Growth 0.4% 0.0%
Gross Margin 0.7% -0.7%
Operating Margin 0.4% -5.6%
EPS 8.42 -7.36
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.